Search the Newsreel

Eton Pharmaceuticals Stock Soars After Huge Q2 Beat And Target Hikes

Eton Pharmaceuticals (ETON) stock surged by 45.78% after reporting a significant Q2 beat, with non-GAAP EPS of $0.43 and revenue of $37.6M, driven by 99% year-over-year growth. The company also raised its 2026 revenue guidance to over $145M and adjusted EBITDA margin to at …

Eton Pharmaceuticals Soars After Blowout Q2 And Guidance Hike

Eton Pharmaceuticals (NASDAQ: ETON) experienced a significant stock surge of over 45% after reporting blowout Q2 earnings and raising its 2026 revenue guidance. The company's Q2 non-GAAP EPS and revenue significantly beat consensus estimates, driven by strong growth and the successful relaunch of Hemangeol. …

86,249 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 86,249 shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, valued at approximately $3.12 million, representing a 0.31% stake in the company. This acquisition comes as Eton Pharmaceuticals reported strong quarterly results, exceeding revenue and EPS expectations, and …

Eton Pharmaceuticals (ETON) Stock Reprices Higher After Profit Inflection

Eton Pharmaceuticals (ETON) stock surged 44.3% to US$58.86 after reporting a significant profit inflection in Q2 2026, with net income reaching US$11.6m and EPS of US$0.42 on US$37.6m revenue. This performance has led to increased revenue guidance for 2026 and supports the company's rare …

Why Eton Pharmaceuticals Is Top of the Class Today

Key Points Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.10 stocks we like better than Eton Pharmaceuticals › Eton Pharmaceuticals (NASDAQ: ETON) stock soared 41.9% through 2:15 …

Princeton Bancorp Director Martin Tuchman Acquires 10,534 Shares in August 2026

Martin Tuchman, a director and 10% stakeholder in Princeton Bancorp, Inc. (NASDAQ:BPRN), acquired 10,534 shares of the company's common stock on August 12, 2026, at a price of $42.978 per share. This open-market purchase, detailed in an SEC Form 4 filing, increases his indirect …

Princeton Bancorp (NASDAQ:BPRN) Director Purchases $452,751.32 in Stock

Princeton Bancorp director Martin Tuchman recently purchased 10,534 shares of the company's stock for $452,751.32, increasing his position by over 77%. This insider buying follows strong quarterly results where Princeton Bancorp exceeded revenue and EPS expectations. The company also declared a $0.35 quarterly dividend, …

Princeton Bancorp (BPRN) insider buys 10,534 shares at $42.978

Princeton Bancorp (BPRN) director and 10% owner Martin Tuchman recently purchased 10,534 shares of common stock at $42.978 per share, held indirectly through The Tuchman Foundation, Inc. This transaction, dated August 12, 2026, increased the foundation's holdings to 24,138 shares. Tuchman also maintains significant …

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day

Eton Pharmaceuticals (ETON) shares surged 40% to an all-time high after better-than-expected Q2 results, driven by the successful relaunch of Hemangeol. The company raised its full-year 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at least 35%. Analysts from B. …

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High Following Earnings Beat

Eton Pharmaceuticals (NASDAQ:ETON) reached a new 52-week high after reporting strong Q2 earnings, with EPS of $0.43 and revenue of $37.59 million, significantly beating analyst estimates. The stock surged 42%, supported by a maintained "Buy" rating and increased price targets from analysts like HC …

Eton Pharmaceuticals stock hits all-time high at 55.07 USD

Eton Pharmaceuticals Inc. stock reached an all-time high of $55.07, currently trading at $54.43, significantly above its 52-week high. Despite appearing overvalued by InvestingPro analysis, the company has seen a 139.44% appreciation over the last year, with its market capitalization at $1.12 billion and …

Eton Pharmaceuticals jumps on strong Q2 print, 2026 guidance

Shares in Eton Pharmaceuticals (ETON [https://seekingalpha.com/symbol/ETON]) rallied 25% in premarket trading on Friday, driven by a solid quarterly print and 2026 revenue forecast, which the company said would exceed $145M while targeting adjusted EBITDA margin above 35%. Chief executive officer Sean Brynjelsen said the …

Duketon Mining (ASX:DKM) Hits Shallow Gold At Barlee As Drilling Campaign Widens

Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35%

Earnings Call Insights: Eton Pharmaceuticals (ETON) Q2 2026 MANAGEMENT VIEW * CEO Sean Brynjelsen said the company delivered “record revenue, significant margin expansion and important progress across both our commercial portfolio and pipeline,” while also completing “several strategic transactions” intended to support long-term growth. …

Eton Pharmaceuticals Q2 2026 Earnings Call Transcript

Eton Pharmaceuticals Q2 Earnings Call Highlights

ETON PHARMACEUTICALS ($ETON) Releases Q2 2026 Earnings, Stock Rises

Eton Pharmaceuticals earnings beat by $0.28, revenue topped estimates

Eton Pharmaceuticals (ETON) reported Q2 earnings of $0.35 per share, significantly beating the Zacks Consensus Estimate of $0.11, and revenues of $37.59 million, surpassing estimates by 38.12%. Despite strong financial performance and a 145.9% stock increase year-to-date, the company currently holds a Zacks Rank …

Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.28 EPS

Eton Pharmaceuticals soars 25% on earnings beat, raised guidance

Eton Pharmaceuticals (NASDAQ:ETON) shares surged 25% after reporting strong second-quarter results that significantly exceeded analyst expectations. The company posted adjusted EPS of $0.43 and revenue of $37.6 million, driven by HEMANGEOL sales and growth in its rare disease portfolio. Eton also raised its full-year …

Eton Pharmaceuticals (NASDAQ: ETON) swings to H1 2026 profit on revenue jump

Eton Pharmaceuticals (NASDAQ: ETON) reported a significant financial turnaround, swinging to a profit in the first half of 2026 with net income of $13.1 million, compared to a net loss of $4.1 million in the same period of 2025. This improvement was driven by …

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

Eton Pharmaceuticals reported record Q2 2026 product sales of $37.6 million, a 99% increase year-over-year, and raised its full-year revenue guidance to over $145 million. The company's strong performance was driven by the successful relaunch of HEMANGEOL and growth across its rare disease portfolio, …

Eton Now Expects 2026 Revenue to Exceed $145M After Q2

Eton Pharmaceuticals reported strong Q2 2026 financial results, with net revenue surging 99% year-over-year to $37.6 million. Driven by the successful relaunch of HEMANGEOL and growth across its rare disease portfolio, the company has raised its full-year 2026 revenue guidance to exceed $145 million …

Eton Pharmaceuticals earnings ahead: Profitability in focus

Eton Pharmaceuticals is expected to report second-quarter earnings with analysts forecasting $0.15 per share on $26.88 million in revenue, a significant improvement from the prior quarter. Investors will be closely watching for continued commercial execution, especially from recent product launches, and evidence that the …

Equities Analysts Issue Forecasts for ETON FY2027 Earnings

What Could Eton Pharmaceuticals (ETON) Gain From The ASN 001 Licensing Deal?

HC Wainwright Brokers Reduce Earnings Estimates for ETON

HC Wainwright has reduced its earnings per share estimates for Eton Pharmaceuticals (NASDAQ:ETON) for Q2 2026 and the full fiscal year 2026, lowering the Q2 estimate to $0.11 from $0.15 and the FY2026 estimate to $0.52, significantly below the broader consensus of $0.75. Despite …

Duketon Mining Issues New Shares Under Secondary Trading Exemption

ETON PHARMACEUTICALS INC : H.C. WAINWRIGHT RAISES TARGET PRICE TO $65 FROM $57

H.C. Wainwright has increased its target price for Eton Pharmaceuticals Inc. (ETON.O) to $65 from the previous $57. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The article also includes a disclaimer that its content is solely the …

Eton Pharmaceuticals Inc expected to post earnings of 11 cents a share - Earnings Preview

Eton Pharmaceuticals Inc is projected to report earnings of 11 cents per share. This information comes from an earnings preview. The full article is available on TradingView, which provides access to content from various news sources.